Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TauRx Pharmaceuticals Ltd.

www.taurx.com

Latest From TauRx Pharmaceuticals Ltd.

Lilly And AC Immune Partner On A Small Molecule With Potential In Alzheimer's Combinations

Eli Lilly signed a licensing deal to develop a tau aggregation inhibitor small molecule for Alzheimer's disease – a drug that works differently from existing antibodies and could offer potential in combination regimens. AC Immune CEO Andrea Pfeifer talked to Scrip about the deal.

Neurology Deals

AbbVie's Alzheimer's Efforts Voyage Into AAV-Targeted Tau Antibodies

Collaboration between Voyager and AbbVie will attempt to produce a single-administration gene therapy targeting tau protein, using adeno-associated vector technology to pass the blood-brain barrier.
Research & Development Deals

Axovant Plans Nelotanserin PhIII But Trial Endpoint Has Eyebrows Raised

Axovant will move its 5HT2A receptor, nelotanserin, into Phase III studies later this year for Lewy body dementia patients, but the company is switching gears to focus on motor function over its previously stated target of visual hallucinations in patients.

Clinical Trials Research & Development

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Southeast Asia
        • Singapore
  • Parent & Subsidiaries
  • TauRx Pharmaceuticals Ltd.
  • Senior Management
  • Seng Shay Way, MD, Mng. Dir.
    Hwang Hong Wei, Dir., Fin.
    Charles Harrington, PhD, CSO
    Tim Earle, CBO
    John Cheung, PhD, Chief Dev. Officer
  • Contact Info
  • TauRx Pharmaceuticals Ltd.
    Phone: (65)
    3 Shenton Way #21-04
    Shenton House
    Singapore, 068805
    Singapore
UsernamePublicRestriction

Register